Insider Selling: Biogen (NASDAQ:BIIB) Insider Sells $531,547.80 in Stock

Biogen Inc. (NASDAQ:BIIB) insider Priya Singhal sold 2,660 shares of the company’s stock in a transaction dated Monday, February 9th. The shares were sold at an average price of $199.83, for a total transaction of $531,547.80. Following the sale, the insider directly owned 8,043 shares in the company, valued at approximately $1,607,232.69. This trade represents a 24.85% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Priya Singhal also recently made the following trade(s):

• On Monday, February 2nd, Priya Singhal sold 748 shares of Biogen stock. The shares were sold at an average price of $179.30, for a total transaction of $134,116.40.

Biogen Stock Performance

Shares of BIIB stock opened at $195.50 on Friday. The firm’s 50 day moving average is $177.92 and its 200 day moving average is $158.38. The stock has a market capitalization of $28.69 billion, a P/E ratio of 22.19, a PEG ratio of 1.52 and a beta of 0.16. Biogen Inc. has a 12 month low of $110.04 and a 12 month high of $202.41. The company has a current ratio of 2.68, a quick ratio of 2.03 and a debt-to-equity ratio of 0.34.

Biogen (NASDAQ:BIIB) last issued its earnings results on Friday, February 6th. The biotechnology company reported $1.99 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.61 by $0.38. The business had revenue of $2.28 billion for the quarter, compared to analysts’ expectations of $2.21 billion. Biogen had a net margin of 13.07% and a return on equity of 12.64%. The business’s revenue for the quarter was down 7.2% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $3.44 EPS. Biogen has set its FY 2026 guidance at 15.250-16.250 EPS. On average, sell-side analysts anticipate that Biogen Inc. will post 15.83 earnings per share for the current year.

Key Stories Impacting Biogen

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Q4 beat and raised FY‑2026 guidance — Biogen reported EPS and revenue above consensus and set FY‑2026 EPS guidance of $15.25–$16.25, which underpins improved earnings visibility and has been a major catalyst for analyst upgrades. Article Title
• Positive Sentiment: Leqembi subcutaneous BLA gets priority review — The subcutaneous formulation (lecanemab) received a priority review designation, which could expand commercial reach and margins if approved. This boosts upside to the Alzheimer’s franchise over the medium term. Article Title
• Positive Sentiment: Analyst upgrades and higher price targets — Several firms lifted targets (Mizuho to $236, Citi, RBC, Canaccord and others raised targets), supporting further upside expectations and trading interest. Article Title
• Positive Sentiment: Institutional accumulation — Major holders (Vanguard, State Street, Geode, Norges Bank, Invesco) either added or maintain large stakes, indicating continued institutional conviction and providing bid support.
• Neutral Sentiment: Board chair transition — Caroline Dorsa is retiring and Dr. Maria C. Freire was elected chair. Governance change reduces uncertainty about succession but is unlikely to be an immediate earnings driver. Article Title
• Neutral Sentiment: Short‑interest data appears unreliable — Published short‑interest entries show zero shares / NaN changes and are internally inconsistent; there’s no clear sign of short‑covering driving today’s move.
• Negative Sentiment: Insider sale — Director/officer Priya Singhal sold 2,660 shares recently (filing shows sales around the $180–$200 range). Insider selling can raise short‑term concern about timing or valuation. Article Title
• Negative Sentiment: Ongoing franchise pressure and execution risk — Analysts and commentary note MS franchise pressures and execution risk around scaling Leqembi access/commercialization, which could cap upside if execution slips. Article Title

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on the company. Stifel Nicolaus upped their price target on Biogen from $202.00 to $214.00 and gave the company a “buy” rating in a research report on Friday, February 6th. Mizuho boosted their price objective on shares of Biogen from $207.00 to $236.00 and gave the company an “outperform” rating in a research note on Tuesday. Wedbush upped their target price on shares of Biogen from $178.00 to $187.00 and gave the stock a “neutral” rating in a report on Monday. Truist Financial raised their price target on shares of Biogen from $190.00 to $193.00 and gave the company a “hold” rating in a report on Monday. Finally, Royal Bank Of Canada boosted their price target on shares of Biogen from $217.00 to $233.00 and gave the company an “outperform” rating in a research report on Monday. Twelve equities research analysts have rated the stock with a Buy rating and fourteen have assigned a Hold rating to the company. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $205.84.

Hedge Funds Weigh In On Biogen

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Rothschild Investment LLC lifted its holdings in shares of Biogen by 12.3% during the 4th quarter. Rothschild Investment LLC now owns 513 shares of the biotechnology company’s stock worth $90,000 after acquiring an additional 56 shares during the last quarter. Advisory Services Network LLC raised its position in Biogen by 3.9% during the third quarter. Advisory Services Network LLC now owns 1,792 shares of the biotechnology company’s stock valued at $251,000 after purchasing an additional 68 shares in the last quarter. CVA Family Office LLC lifted its stake in Biogen by 18.1% during the third quarter. CVA Family Office LLC now owns 464 shares of the biotechnology company’s stock worth $65,000 after purchasing an additional 71 shares during the last quarter. Davis Investment Partners LLC boosted its holdings in shares of Biogen by 1.7% in the 4th quarter. Davis Investment Partners LLC now owns 4,374 shares of the biotechnology company’s stock worth $778,000 after purchasing an additional 71 shares in the last quarter. Finally, Optas LLC increased its position in shares of Biogen by 4.5% during the 4th quarter. Optas LLC now owns 1,706 shares of the biotechnology company’s stock valued at $300,000 after purchasing an additional 73 shares during the last quarter. Hedge funds and other institutional investors own 87.93% of the company’s stock.

Biogen Company Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.